Storia: AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC

WARPTECHNEWS · LAB

The FDA has approved the TROP2-directed ADC Datroway as a first-line option for triple-negative breast cancer, giving Daiichi Sankyo and AstraZeneca a leg up over their competitor…

AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC

Confronto fonti

AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC

Timeline cronologica

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple…

FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval

FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of…

AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway

New First-Line Option Approved in Triple-Negative Breast Cancer

AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway

AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC

New First-Line Option Approved in Triple-Negative Breast Cancer